Lipocine Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| LPCN | LEXX | DARE | ABVC | CELZ | 18H0.F | |
|---|---|---|---|---|---|---|
| Market cap | 11.87M | 8.57M | 13.02M | 26.69M | 4.95M | 5.11M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -1.2 | -10.4 | -1.3 | -2.3 | -0.7 | — |
| Price/book | 0.5 | 1.4 | -17.9 | 2.5 | 0.5 | -1.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −42.97% | −75.12% | −64.67% | −65.92% | −75.95% | −38.46% |
| Today | −1.37% | +0.99% | +1.83% | +1.51% | −3.21% | −23.81% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All LPCN news ›Financial Survey: Lipocine (NASDAQ:LPCN) & Theravance Biopharma (NASDAQ:TBPH)
Posted by Defense World Staff on Oct 25th, 2026 Theravance Biopharma (NASDAQ:TBPH – Get Free Report) and Lipocine (NASDAQ:LPCN – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will…
Lipocine updates corporate investor presentation
Lipocine Inc. (LPCN) updated the corporate presentation it uses in meetings with investors, analysts and others, and filed the presentation as an exhibit. Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of…
Lipocine (NASDAQ: LPCN) wins Health Canada approval for TLANDO in Canada
Posted by Michael Walen on Oct 10th, 2026 Verity Pharma is planning launch and commercialization in the Canadian market by the end of 2026. The release also says Verity Pharma is responsible for regulatory and commercialization obligations…
Head-To-Head Contrast: Lipocine (NASDAQ:LPCN) versus Harmony Biosciences (NASDAQ:HRMY)
Posted by Tristan Rich on Oct 9th, 2026 Lipocine (NASDAQ:LPCN – Get Free Report) and Harmony Biosciences (NASDAQ:HRMY – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses…
Lipocine (LPCN) Advances BLOOM Trial As Traders Eye Cash Runway
Lipocine Inc. stocks have been trading up by 5.6 percent following strong positive sentiment around its latest clinical trial progress. Key Takeaways Lipocine has initiated BLOOM, a Phase 3 trial of its oral brexanolone candidate LPCN 1154…
Lipocine (LPCN) Jumps As BLOOM Phase 3 Trial Kicks Off
Lipocine Inc. surged as pivotal clinical trial success fueled bullish sentiment, and stocks have been trading up by 67.63 percent For active traders, LPCN is a classic high‑risk, high‑reward biotech setup. Lipocine Inc. is still a…
More from 1 other outlet
Lipocine Jumps On TLANDO's Health Canada Approval For Testosterone Replacement Therapy
Following the news, Lipocine shares rose more than 25% to $2.64. TLANDO is an oral formulation of testosterone undecanoate available as 112.5 mg capsules. In January 2024, Lipocine and Verity Pharma entered into an exclusive licensing…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- stocktitan.net2
- themarketsdaily.com2
- timothysykes.com2
- defenseworld.net1
- rttnews.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.